
Swiss biopharmaceutical company, Polyphor, has announced that its global Phase III study, FORTRESS, evaluating balixafortide (POL6326) in combination with eribulin …

AstraZeneca has failed to reach the primary endpoint in their Storm Chaser trial, assessing the safety and efficacy of AZD7442, …

Acasti Pharma’s shares plunged by as much as 67% this week as its drug CaPre failed to meet its primary …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

